Drugs / JNJ-39220675
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00804687 | Nov 2008 → Feb 2009 | allergic rhinitis | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-39220675 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00804687 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL1171754 ↗ |
| Modality | Small molecule | — CHEMBL1171754 ↗ |
| Route | Oral | “will be administered as 1 ml of 10 milligram/milliliter solution orally” NCT00804687 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL1171754 ↗ |